Edition:
United States

Galectin Therapeutics Inc (GALT.OQ)

GALT.OQ on NASDAQ Stock Exchange Capital Market

2.36USD
25 May 2017
Change (% chg)

$0.01 (+0.43%)
Prev Close
$2.35
Open
$2.36
Day's High
$2.41
Day's Low
$2.29
Volume
16,406
Avg. Vol
97,319
52-wk High
$3.67
52-wk Low
$0.49

GALT.OQ

Chart for GALT.OQ

About

Galectin Therapeutics Inc. is a clinical-stage biopharmaceutical company engaged in drug research and development to create therapies for fibrotic disease and cancer. The Company's drug candidates are based on its method of targeting galectin proteins, which are mediators of biologic and pathologic functions. It uses naturally... (more)

Overall

Beta: 2.48
Market Cap(Mil.): $81.82
Shares Outstanding(Mil.): 34.67
Dividend: --
Yield (%): --

Financials

  GALT.OQ Industry Sector
P/E (TTM): -- 141.29 17.43
EPS (TTM): -0.68 -- --
ROI: -134.19 2.17 -5.41
ROE: -326.49 0.10 -4.69

BRIEF-Galectin Therapeutics Q1 loss per share $0.15

* Galectin therapeutics reports 2017 first quarter financial results and provides business update

May 15 2017

BRIEF-Galectin Therapeutics receives notice of Japanese decision to grant a composition of matter patent for GR-MD-02

* Galectin Therapeutics receives notice of Japanese decision to grant a composition of matter patent for GR-MD-02

Apr 25 2017

BRIEF-Galectin Therapeutics says co had $15.4 mln of non-restricted cash and cash equivalents as of December 31 2016

* Galectin Therapeutics Inc - as of December 31, 2016, company had $15.4 million of non-restricted cash and cash equivalents - sec filing

Mar 28 2017

BRIEF-Galectin Therapeutics drug demonstrates clinically significant effect in eczema patients

* Galectin Therapeutics Inc - GR-MD-02 demonstrates clinically significant effect in patients with severe and refractory atopic dermatitis (eczema)

Mar 14 2017

BRIEF-Galectin Therapeutics has says can cover expenditures through 2017 - SEC filing

* Has generated sufficient financing to cover currently planned expenditures through 2017 - sec filing

Feb 01 2017

BRIEF-Richard Uihlein reports 7.89 pct stake in Galectin Therapeutics

* Richard Uihlein reports 7.89 percent stake in Galectin Therapeutics Inc as of Dec 22 - SEC filing Source text: (http://bit.ly/2jMCBRA) Further company coverage:

Jan 18 2017

More From Around the Web

Competitors

  Price Chg
Novartis AG (NOVN.S) CHF78.60 -0.50
Merck & Co., Inc. (MRK.N) $65.04 +0.11
Roche Holding Ltd. (ROG.S) CHF266.60 -0.60
Roche Holding Ltd. (RO.S) CHF267.75 +0.25
Eli Lilly and Co (LLY.N) $78.34 +0.38
Momenta Pharmaceuticals, Inc. (MNTA.OQ) $15.00 -0.25

Earnings vs. Estimates